We are proud to announce that our CEO, Paul Tanico, was recently interviewed by Global Business Reports to discuss the impacts of our Discern™ Test which diagnoses Alzheimer's with unprecedented accuracy. The full article can be read here: https://www.gbreports.com/interview/paul-tanico…Read More
The U.S. Food and Drug Administration has granted Breakthrough Device designation to DISCERN, a biomarker test for Alzheimer’s. The test was developed using blood and tissue samples that were monitored and evaluated by WVU’s Rockefeller Neurosciences Institute. If the test gains full approval,…Read More
DISCERN™ is the most accurate, least invasive and most cost effective test for identifying Alzheimer’s Disease (Rockville, MD) October 15, 2018 – NeuroDiagnostics, LLC, a privately held neurological diagnostics company, announced today that the US Food and Drug Administration (FDA) has granted…Read More